Roche’s gantenerumab fails to meet primary endpoint in AD trial

Roche’s investigational medicine gantenerumab has failed to achieve its primary endpoint in the Phase II/III Alzheimer’s disease (AD) trial. The gantenerumab arm of phase II/III DIAN-TU-001 study has failed to meet its primary endpoint in people who have an early-onset, inherited form of AD or otherwise known as autosomal dominant AD (ADAD).